Xifaxan Approved for IBS-D
May 27, 2015 – The U.S. Food and Drug Administration (FDA) approved Xifaxan® (rifaximin), manufactured by Salix, to treat adults with irritable bowel syndrome with diarrhea (IBS-D). Irritable bowel syndrome which is characterized mainly by loose or watery stools at least 25 percent of the time is estimated to affect about 10 to 15 percent of adults in the United States.
Xifaxan is an antibacterial drug that received a new indication for treating patients with IBS-D. The recommended dose is 550mg three times daily for 14 days. Patients who experience a recurrence of symptoms can be retreated up to two times with the same dosage regimen. Originally, Xifaxan was previously approved as a treatment for travelers' diarrhea caused by E. coli and to reduce the risk in adults with recurring overt hepatic encephalopathy.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.